Table 1.
Osteoporosis therapies in use1
| Drug class | Drugs | Action on bone remodeling | Action on bone mineral density | Action on vertebral and nonvertebral fracture risk |
|---|---|---|---|---|
| Antiresorptive agents | Aminobisphosphonates | ↓↓ | ↑ | V ↓; NV ↓ |
| Raloxifene | ↓ | ↑ | V ↓ | |
| Denosumab | ↓↓↓ | ↑ | V ↓; NV ↓ | |
| Uncoupling agent | Strontium ranelate | ↓ OC, ↑OB | ↑ | V ↓; NV ↓ |
| Anabolic agents | PTH 1–84 | ↑ | ↑↑ | V ↓; NV ↓ |
| Teriparatide | ↑ | ↑↑ | V ↓; NV ↓ |
Notes: ↑ increase; ↓ decrease; ↑↑ or ↓↓ strong increase or decrease, respectively. Adapted from International Journal of Clinical Rheumatology, June 2011, Vol. 6, No. 3, Pages 359–369 with permission of Future Medicine Ltd.
Abbreviations: OB, osteoblast; OC, osteoclast; NV, nonvertebral; PTH, parathyroid hormone; V, vertebral.